Kymera Therapeutics, Inc. 4

Kymera Therapeutics’ Chief Medical Officer Terence Rooney was granted 38,000 RSUs and options for 76,000 shares of common stock at a $110.05 exercise price on July 27, 2026.

On July 27, 2026, Kymera Therapeutics’ Chief Medical Officer, Terence Rooney, received an equity compensation package consisting of 38,000 restricted stock units (each RSU representing one share of common stock upon vesting) and a stock option grant covering 76,000 shares of common stock with an exercise price of $110.05 per share. The RSUs will vest in four equal annual installments following July 27, 2026, contingent on continued employment, while 25% of the option grant will vest on July 27, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also subject to continued employment. These are new awards rather than open-market purchases or sales, and they significantly increase the CMO’s potential equity stake in the company on a long-term, performance/tenure-based vesting schedule.

Filing Facts

CIK

1815442

Ticker

KYMR

Form

4

Source Type

fda

Accession

0001193125-26-318408

Alert Tier

6